Studies of Pancreatic Cancer Utilizing Monoclonal Antibodies

Overview

Journal Int J Pancreatol

Specialty Gastroenterology

Date 1990 Aug 1

PMID 1964470

Citations 3

Authors

M Buchler

H Friess

P Malfertheiner

K H Schultheiss

K H Muhrer

H P Kraemer

H G Beger

Affiliations

Soon will be listed here.

Abstract

Since 1985, 150 patients with pancreatic ductal adenocarcinoma have been treated with the monoclonal antibody BW 494 in four different multicentric trials in Germany. The antibody recognizes a human pancreatic cancer associated antigen and mediates an antibody dependent cellular cytotoxicity (ADCC) in vitro, when human mononuclear cells are coincubated as effector cells. In patients with at advanced unresectable pancreatic cancer there where two phase-I-studies finished in 1987 and 1989, respectively, and one uncontrolled phase-II-study finished in 1988. In 1987, we started a controlled randomized trial in patients with resectable (Whipple) pancreatic cancer, which will be finished in 1990. There were no major side effects if the intravenous antibody application was restricted to a 10-d treatment protocol (up to 370 mg given in 10 different dosages). Human anti-mouse-antibodies could be demonstrated in all patients investigated for within 4 wk after immunotherapy. In patients with advanced pancreatic cancer (n = 87), monoclonal antibody treatment did not induce significant response rates. There was stable disease in 1/3 to 1/2 of the patients lasting three months or longer. Therapeutic success may be expected in patients with minor tumor burden.

Citing Articles

Expression of 17-1A antigen and complement resistance factors CD55 and CD59 on liver metastasis in colorectal cancer.

Hosch S, Scheunemann P, Luth M, Inndorf S, Stoecklein N, Erbersdobler A J Gastrointest Surg. 2002; 5(6):673-9.

PMID: 12086907 DOI: 10.1016/s1091-255x(01)80111-6.

Pancreatic cancer: a review of emerging therapies.

Rosenberg L Drugs. 2000; 59(5):1071-89.

PMID: 10852640 DOI: 10.2165/00003495-200059050-00004.

Adjuvant therapy of pancreatic cancer using monoclonal antibodies and immune response modifiers.

Friess H, Gassmann M, Buchler M Int J Pancreatol. 1997; 21(1):43-52.

PMID: 9127173 DOI: 10.1007/BF02785919.

References

Paul A, Engstrom P, Weiner L, Steplewski Z, KOPROWSKI H . Treatment of advanced measurable or evaluable pancreatic carcinoma with 17-1A murine monoclonal antibody alone or in combination with 5-fluorouracil, adriamycin and mitomycin (FAM). Hybridoma. 1986; 5 Suppl 1:S171-4. View

Sindelar W, Maher M, Herlyn D, Sears H, Steplewski Z, KOPROWSKI H . Trial of therapy with monoclonal antibody 17-1A in pancreatic carcinoma: preliminary results. Hybridoma. 1986; 5 Suppl 1:S125-32. View

Montz R, Klapdor R, ROTHE B, Heller M . Immunoscintigraphy and radioimmunotherapy in patients with pancreatic carcinoma. Nuklearmedizin. 1986; 25(6):239-44. View

Tempero M, Pour P, Uchida E, Herlyn D, Steplewski Z . Monoclonal antibody CO17-1A and leukapheresis in immunotherapy of pancreatic cancer. Hybridoma. 1986; 5 Suppl 1:S133-8. View

Malt R . Treatment of pancreatic cancer. JAMA. 1983; 250(11):1433-7. View

Bosslet K, Kern H, Kanzy E, Steinstraesser A, Schwarz A, Luben G . A monoclonal antibody with binding and inhibiting activity towards human pancreatic carcinoma cells. I. Immunohistological and immunochemical characterization of a murine monoclonal antibody selecting for well differentiated adenocarcinomas of the.... Cancer Immunol Immunother. 1986; 23(3):185-91. PMC: 11038228. DOI: 10.1007/BF00205648. View

Buchler M, Kubel R, Malfertheiner P, Friess H, Schulz G, Bosslet K . [Immunotherapy of advanced pancreatic carcinoma with the monoclonal antibody BW 494]. Dtsch Med Wochenschr. 1988; 113(10):374-80. DOI: 10.1055/s-2008-1067647. View

Moossa A . Pancreatic cancer: approach to diagnosis, selection for surgery and choice of operation. Cancer. 1982; 50(11 Suppl):2689-98. View

Gudjonsson B . Cancer of the pancreas. 50 years of surgery. Cancer. 1987; 60(9):2284-303. DOI: 10.1002/1097-0142(19871101)60:9<2284::aid-cncr2820600930>3.0.co;2-v. View

10.

. Comparative therapeutic trial of radiation with or without chemotherapy in pancreatic carcinoma. Gastrointestinal Tumor Study Group. Int J Radiat Oncol Biol Phys. 1979; 5(9):1643-7. DOI: 10.1016/0360-3016(79)90789-2. View

11.

Beger H, Bittner R . [Operative therapy of cancer of the head of the pancreas--determination of surgical status]. Z Gastroenterol. 1985; 23(5):240-6. View

12.

Warshaw A, Swanson R . Pancreatic cancer in 1988. Possibilities and probabilities. Ann Surg. 1988; 208(5):541-53. PMC: 1493791. DOI: 10.1097/00000658-198811000-00001. View

13.

Klapdor R, Lander S, Bahlo M, Montz R . Radioimmunotherapy of xenografts of human pancreatic carcinomas--intravenous and intratumoral application of 131I-labelled monoclonal antibodies. Nuklearmedizin. 1986; 25(6):235-8. View

14.

Schorlemmer H, Bosslet K, Kern H, Sedlacek H . Similarities in function between pancreatic tumor cells and macrophages and their inhibition by murine monoclonal antibodies. Behring Inst Mitt. 1988; (82):240-64. View

15.

Sears H, Atkinson B, Mattis J, Ernst C, Herlyn D, Steplewski Z . Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet. 1982; 1(8275):762-5. DOI: 10.1016/s0140-6736(82)91811-6. View